الصفحة 1 من عند 37 النتائج
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to methods of diagnosing and treating inflammation, particularly inflamed atherosclerotic plaque at risk of rupture or thrombosis. More particularly, the methods of the invention pertain to the simultaneous
BACKGROUND OF THE INVENTION
The invention is in the fields of neurology and pharmacology and relates to protecting the brain and central nervous system against damage due to ischemia and other neurological disorders in which energy-providing substrates (oxygen and glucose) are reduced or energy
FIELD OF THE INVENTION
This invention is in the field of medicinal chemistry. In particular, this invention relates to N,N'-disubstituted guanidine analogues, and to compounds and pharmaceutical composition comprising the same, which possess neuroprotective capability. This invention further relates
BACKGROUND OF THE INVENTION
This invention relates to N,N'-disubstituted guanidine analogues, and to compounds and pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods for treating any disease of the nervous system in
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
FIELD OF THE INVENTION
This invention relates to tri- and tetra-substituted guanidines, and to pharmaceutical compositions comprising the same, which possess neuroprotective capability. This invention further relates to methods involving the use of these compounds as excitatory amino acid
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-dione type. The fused ring system is substituted at the a- or b-position by amino acid derivatives. The compounds are active as excitatory amino
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a- or b-position by amino acid derivatives. The compounds are active as excitatory amino
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The